SequelSEC

Sonoma Pharmaceuticals, Inc. SNOA

Surgical & Medical Instruments & Apparatus · CIK 0001367083 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$21.92M
Fiscal year ended 2026-06-30
Operating income
-$1.41M
Fiscal year ended 2026-06-30
Free cash flow
-$2.66M
Fiscal year ended 2026-06-30

Sonoma Pharmaceuticals, Inc. (SNOA) reported revenue of $21.92M and net income of -$2.26M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Sonoma Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Sonoma Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$21.92M
Cost of revenue$13.39M
Gross profit$8.53M
Operating income-$1.41M
Net income-$2.26M
Research & development$2.27M
Weighted-average diluted sharesUnavailable
Pretax income-$2.51M
Income tax expense-$243.00K
Diluted EPSUnavailable
Selling, general & administrative$7.66M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Sonoma Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$5.34M
Total assets$18.11M
Current assets$16.27M
Total liabilities$11.51M
Current liabilities$5.45M
Total equity incl. NCI$6.59M
Temporary (mezzanine) equityUnavailable
Inventory$3.79M
Accounts receivable$3.18M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.19M

Cash flow

Sonoma Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$2.57M
Capital expenditures$88.00K
Investing cash flow-$88.00K
Financing cash flow$3.99M
Net change in cash$1.73M
Stock-based compensation$256.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Sonoma Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$2.66M
Gross margin38.9%
Operating margin-6.4%
FCF margin-12.1%
SBC / revenue1.2%
Current ratio2.99x
Revenue YoY growth47.0%
Net margin-10.3%
R&D / revenue10.4%
CapEx / revenue0.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SNOA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-K · Filed 2026-06-16View SEC filing
10-Q · Filed 2026-02-10View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-K · Filed 2025-06-17View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.